Multimodality therapy for advanced and recurrent vulvar squamous cell carcinoma: A pilot project

L. F. Carson, L. B. Twiggs, L. L. Adcock, K. A. Prem, R. A. Potish

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


From 1985 to 1989 eight women with advanced or recurrent vulvar carcinoma were treated at the Women's Cancer Center of the University of Minnesota Hospital and Clinic. Each received a combination of 5-fluorouracil, mitomycin C and cisplatin during radiotherapy. Five of the eight women who underwent posttreatment radical vulvectomy had acceptable operative morbidity. Six patients experienced a complete clinical response. Of them, one had microscopic residual disease in the surgical specimen. One patient with recurrent vulvar carcinoma experienced progression of disease on therapy. One death was attributable to chemotherapy toxicity, and two patients died of intercurrent disease. The overall survival rate at 27 months was 33%. This multimodality approach to the treatment of advanced vulvar carcinoma should be considered when designing a therapeutic approach to treating extensive or resistant vulvar carcinoma.

Original languageEnglish (US)
Pages (from-to)1029-1032
Number of pages4
JournalJournal of Reproductive Medicine for the Obstetrician and Gynecologist
Issue number11
StatePublished - Dec 1 1990


Dive into the research topics of 'Multimodality therapy for advanced and recurrent vulvar squamous cell carcinoma: A pilot project'. Together they form a unique fingerprint.

Cite this